EUSA, Jazz Pharmaceuticals deal

Jazz will acquire cancer-focused specialty pharma EUSA for $650 million in cash, plus a potential $50 million payment tied to 2013 U.S. sales of EUSA's Erwinaze. Jazz, which had 2011 revenue of $272.3 million, expects the deal to provide $210-$230 million in additional revenue in 2013.

Erwinaze, an Erwinia chrysanthemi-derived asparaginase, is approved in the U.S., Canada, U.K. and several EU member states to treat acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to Escherichia coli-derived asparaginase and -pegaspargase chemotherapy drugs. EUSA's other marketed products include ALL drug Kidrolase L-asparaginase and mucositis therapy Caphosol supersaturated calcium phosphate. EUSA had 1Q12 net sales of about $46 million. ...